Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 12, 2025 16:05 ET | Source: Korro Bio, Inc.

Korro Reports Third Quarter Financial Results, Provides Updates on KRRO-110 in Alpha-1 Antitrypsin Deficiency and Additional Pipeline Programs

CAMBRIDGE, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- —KRRO-110 produced functional protein in Alpha-1 Antitrypsin Deficiency (AATD) patients —KRRO-110 did not reach projected levels of functional...
September 02, 2025 16:30 ET | Source: Korro Bio, Inc.

Korro to Participate in Upcoming Investor and Scientific Conferences

CAMBRIDGE, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that members of management will participate in the following upcoming investor and...
August 12, 2025 07:00 ET | Source: Korro Bio, Inc.

Korro Reports Second Quarter 2025 Financial Results and Provides Business Updates

— Interim readout from Phase 1/2a REWRITE clinical trial of KRRO-110 on track for the second half of 2025 — Completed dosing of over 80% of planned REWRITE healthy volunteers across multiple single...
July 21, 2025 08:00 ET | Source: Korro Bio, Inc.

Korro Receives European Medicines Agency Orphan Drug Designation for KRRO-110

CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on...
May 14, 2025 16:05 ET | Source: Korro Bio, Inc.

Korro to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that members of management will participate in the following upcoming investor conferences: ...
May 07, 2025 16:30 ET | Source: Korro Bio, Inc.

Korro Reports First Quarter 2025 Financial Results and Provides Business Updates

—Interim readout from Phase 1/2a REWRITE clinical trial of KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD) on track for the second half of 2025 —Streamlining operations and focusing on delivering...
April 01, 2025 07:30 ET | Source: Korro Bio, Inc.

Korro Appoints Biotech Industry Veteran, Loïc Vincent, Ph.D., as Chief Scientific Officer

CAMBRIDGE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based...
March 18, 2025 07:00 ET | Source: Korro Bio, Inc.

Korro Reports Full Year 2024 Financial Results and Provides Business Updates

—Completed dosing of first two cohorts in Phase 1/2a REWRITE Clinical Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD); Interim readout expected in the second half of 2025 —U.S. Food and...
March 14, 2025 08:00 ET | Source: Korro Bio, Inc.

KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency

CAMBRIDGE, Mass., March 14, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based...
February 26, 2025 08:00 ET | Source: Korro Bio, Inc.

Korro to Present at the TD Cowen 45th Annual Health Care Conference

CAMBRIDGE, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on...